Meningococcal Vaccine Study in Adults

Research area: Infection and Immunity | Status: Active

People doing research

The Vaccine and Immunisation Research Group (VIRGo) is conducting a research study on a vaccine against meningococcal type A,C,W,Y infections in healthy adults between 18 and 40 years.

This study compares the body’s ability to produce antibodies against the study vaccines, as well as the safety of a new liquid formulation of the MenACWY vaccine with a registered MenACWY vaccine.

This study compares the body’s ability to produce antibodies against the study vaccines, as well as the safety of a new liquid formulation of the MenACWY vaccine with a registered MenACWY vaccine.

Overview

The Vaccine and Immunisation Research Group (VIRGo) of the Murdoch Childrens Research Institute in collaboration with The University of Melbourne is conducting a research study on a vaccine against meningococcal type A,C,W,Y infections in healthy adults between 18 and 40 years.

What is meningococcal disease?

Neisseria meningitidis or meningococcus is a family of germs (bacteria) that can cause meningitis, which is an infection of the surface of the brain. While meningitis is a rare infection, it can be life-threatening and lead to permanent disability.

These bacteria can also cause an infection of the blood, called sepsis. The most common groups in the meningococcus family that can cause disease are groups A, B, C, W and Y.

What is the study about?

This study is comparing the body’s ability to produce antibodies against the study vaccines, as well as the safety of a new liquid formulation of the MenACWY vaccine with a registered MenACWY vaccine.

972 people between 18 and 40 years of age will take part in the study including ~170 in Australia.

Information for participants

Who can participate?

Participants must be:

  • Aged 18 - 40 years, and
  • Are healthy

Get involved 

For more information, please contact the study staff at the Vaccine and Immunisation Research Group. If you join the study, you will:

  • receive one dose of either the MenACWY liquid study vaccine or a registered MenACWY vaccine by injection
  • need to visit the study site two times, one month apart and have a phone call at two weeks, three months and six months after vaccination.

 

Contact us

Vaccine and Immunisation Research Group
Meningococcal Vaccine Study in Adults
Murdoch Children's Research Institute
The Royal Children's Hospital
50 Flemington Road
Parkville VIC 3052
Australia

Ph: +61 3 8344 9325
Email: [email protected]
SMS:  0407 548 086

 
  
child in hospital

Tomorrow's cures need your donations today

Donate now